JUŘICA, Jan and Alexandra ŽOURKOVÁ. Dynamics and persistence of CYP2D6 inhibition by paroxetine. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. HOBOKEN: WILEY-BLACKWELL, 2013, vol. 38, No 4, p. 294-300. ISSN 0269-4727. Available from: https://dx.doi.org/10.1111/jcpt.12042.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Dynamics and persistence of CYP2D6 inhibition by paroxetine
Authors JUŘICA, Jan (203 Czech Republic, guarantor, belonging to the institution) and Alexandra ŽOURKOVÁ (203 Czech Republic, belonging to the institution).
Edition JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, HOBOKEN, WILEY-BLACKWELL, 2013, 0269-4727.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.533
RIV identification code RIV/00216224:14740/13:00065968
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/jcpt.12042
UT WoS 000321339800006
Keywords in English CYP2D6; disinhibition; paroxetine
Tags ok, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 10/12/2013 10:21.
Abstract
What is known and Objective Paroxetine is both a substrate and an inhibitor of CYP2D6. The objective of the presented study was to determine the persistence of CYP2D6 inhibition after short term (6 weeks) and long term (18,7 +/- 10,6 weeks) paroxetine treatment. Methods: Two the studies consisted of 30 depressive/anxiety patients each. In the first study, patients were subdivided into three groups treated with paroxetine (A1), alprazolam (A2) and paroxetine + alprazolam (A3). After 6 weeks, all the patients (A1+A2+A3) were switched to alprazolam treatment; metabolic activity was evaluated at the beginning, after 6 weeks of paroxetine/alprazolam/alprazolam + paroxetine treatment (A1/A2/A3) and 4 weeks after the switch to alprazolam treatment (Week 0, 6, 10). In the second study patients on previous long term paroxetine treatment were subdivided into two groups treated with mirtazapine (B1) or paroxetine (B2); metabolic activity of CYP2D6 was evaluated at the beginning and after 6 weeks of therapy. Results and Discussion: Metabolic ratio of dextromethorphan to dextrorphan has normalized in all subjects after 4 weeks of paroxetine wash out in the first study. In the second study, 6 weeks after paroxetine discontinuation, restoration of metabolic activity of CYP2D6 was observed in only five of eight originally poor metabolizers. What is new and Conclusion: We conclude that a wash-out period of 4 weeks seems to be sufficient for CYP2D6 disinhibition after short-term paroxetine treatment (6 weeks). On the other hand, treatment with a CYP2D6 substrate less than 6 weeks after long-term paroxetine treatment (18.7 weeks on average) could result in elevated drug plasma levels and occasionally also in drug toxicity.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
GAP206/10/0057, research and development projectName: Miniaturizovaný systém pro "on-line" studie metabolismu léčiv založený na kapilární elektroforéze
Investor: Czech Science Foundation, Miniaturized on-line drug metabolism system based on capillary electrophoresis
PrintDisplayed: 4/8/2024 22:14